文献速递前列腺癌

11C-乙酸盐正电子发射断层显像/计算机断层显像在前列腺癌根治性前列腺切除或放疗后复发灶检测中的应用

11C-acetate positron-emission tomography/computed tomography imaging for detection of recurrent disease after radical prostatectomy or radiotherapy in patients with prostate cancer.
PubMed 文献 · BJU Int · 2016-12-05

该前瞻性研究纳入103例根治性前列腺切除(97例)或放疗(6例)后PSA复发的前列腺癌患者,行11C-乙酸盐PET/CT检查,42例阳性。25例提示淋巴结转移者中19例经手术或放疗证实为真阳性(阳性预测值76%),17例远处转移者接受全身治疗。作者认为仅少数复发患者可从AC-PET指导的局部治疗中获益。

要点

  • 103例PSA复发患者中42例AC-PET阳性,25例提示淋巴结转移、17例提示远处转移。
  • 淋巴结转移患者中19/25为真阳性,阳性预测值76%,假阳性提示非肿瘤代谢因素可致AC摄取增高。
  • AC-PET阳性患者局部治疗后中位无复发时间为6个月(范围5-9个月),短于预期。

核心结论

  • 仅少数PSA复发的前列腺癌患者可能从AC-PET指导的局部治疗中获益。
  • 假阳性结果提示除肿瘤代谢外,其他因素也可诱导AC摄取增加。
  • 局部治疗后无复发时间短于预期。

研究设计与样本

  • 前瞻性研究,纳入103例根治性前列腺切除(n=97)或放疗(n=6)后PSA复发的前列腺癌患者,行11C-乙酸盐PET与CT匹配显像。
  • AC-PET阳性且为局部复发者切除病灶行组织学验证,或局部放疗后以PSA随访;AC-PET示远处转移者接受雄激素剥夺/化疗。

主要发现

  • 103例中42例AC-PET阳性;PSA<1.0、<2.0和<4.0 ng/mL者分别为6、16和20例。
  • 42例中25例AC-PET提示淋巴结转移:16/25手术(10/16为转移,6/16为炎症),9/25行淋巴结转移灶放疗后PSA下降。
  • 42例中17例AC-PET示远处转移,开始全身治疗。
  • 手术与放疗患者合计,19/25为真阳性(阳性预测值76%);其中5/19 PSA<2.0 ng/mL,2/19 PSA<1.0 ng/mL,14/19 PSA为5.4-23.1 ng/mL。
  • 手术或放疗后AC-PET阳性(未行雄激素剥夺)患者再次PSA升高的中位时间(范围)为6(5-9)个月。

临床怎么用

  • 作者认为仅少数PSA复发的前列腺癌患者可能从AC-PET指导的局部治疗中获益。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate, in a prospective study, the effectiveness of computed tomography (CT)-matched 11C-acetate (AC) positron-emission tomography (PET) in patients with prostate cancer (PCa) who had prostate-specific antigen (PSA) relapse after radical prostatectomy (RP) or radiotherapy (RT). PATIENTS AND METHODS: In 103 relapsing patients after RP (n = 97) or RT (n = 6) AC-PET images and CT scans were obtained. In patients with AC-PET-positive results with localized PCa recurrence, detected lesions were resected and histologically verified or, after local RT, followed-up by PSA testing. Patients with distant disease on AC-PET were treated with androgen deprivation/chemotherapy. RESULTS: Of 103 patients, 42 were AC-PET-positive. PSA levels were <1.0, <2.0 and <4.0 ng/mL in six, 16 and 20 patients, respectively. In 25/42 patients AC-PET suggested lymph node metastases: 16/25 patients underwent surgery (10/16 metastasis, 6/16 inflammation); 9/25 patients underwent RT of lymph node metastases, which was followed by decreasing PSA level. In 17/42 patients who had distant disease, systemic treatment was commenced. Combining patients who underwent surgery and those who underwent RT, 19/25 patients were true-positive in terms of AC-PET (positive predictive value 76%). In 5/19 patients, PSA level was <2.0 ng/mL, in 2/19 patients it was <1.0 ng/mL and in 14/19 patients it was 5.4-23.1 ng/mL. In AC-PET-positive patients after surgery or RT (without androgen deprivation), median (range) time to renewed PSA increase was 6 (5-9) months. CONCLUSIONS: Only a minority of patients with relapsing PCa appear to benefit from AC-PET for guiding potential local treatment. False-positive results show that factors other than tumour metabolism induce increased AC uptake. The time free of recurrence after local treatment was shorter than expected.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Esch LH, Fahlbusch M, Albers P, et al. 11C-acetate positron-emission tomography/computed tomography imaging for detection of recurrent disease after radical prostatectomy or radiotherapy in patients with prostate cancer. BJU Int. 2016. PMID: 27860163. doi:10.1111/bju.13706

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。